malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication
- PMID: 29190291
- PMCID: PMC5708606
- DOI: 10.1371/journal.pmed.1002455
malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication
Abstract
Since the turn of the century, a remarkable expansion has been achieved in the range and effectiveness of products and strategies available to prevent, treat, and control malaria, including advances in diagnostics, drugs, vaccines, and vector control. These advances have once again put malaria elimination on the agenda. However, it is clear that even with the means available today, malaria control and elimination pose a formidable challenge in many settings. Thus, currently available resources must be used more effectively, and new products and approaches likely to achieve these goals must be developed. This paper considers tools (both those available and others that may be required) to achieve and maintain malaria elimination. New diagnostics are needed to direct treatment and detect transmission potential; new drugs and vaccines to overcome existing resistance and protect against clinical and severe disease, as well as block transmission and prevent relapses; and new vector control measures to overcome insecticide resistance and more powerfully interrupt transmission. It is also essential that strategies for combining new and existing approaches are developed for different settings to maximise their longevity and effectiveness in areas with continuing transmission and receptivity. For areas where local elimination has been recently achieved, understanding which measures are needed to maintain elimination is necessary to prevent rebound and the reestablishment of transmission. This becomes increasingly important as more countries move towards elimination.
Conflict of interest statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: FB is a full-time employee of Sanofi, a manufacturer of antimalarial medicines. JV was a full time employee of GlaxoSmithKline Biologicals at the time of the panel consultation.
Figures
References
-
- World Health Organization. Eliminating malaria Geneva: WHO; 2016. [Available from: http://apps.who.int/iris/bitstream/10665/205565/1/WHO_HTM_GMP_2016.3_eng...]
-
- World Health Organization; Global technical strategy for malaria 2016–2030 Geneva: WHO; 2015. [Available from: http://apps.who.int/iris/bitstream/10665/176712/1/9789241564991_eng.pdf]
-
- malERA Consultative Group on Vector Control. A research agenda for malaria eradication: vector control. PLoS Med. 2011;8(1):e1000401 doi: 10.1371/journal.pmed.1000401 - DOI - PMC - PubMed
-
- malERA Consultative Group on Vaccines. A research agenda for malaria eradication: vaccines. PLoS Med. 2011;8(1):e1000398 doi: 10.1371/journal.pmed.1000398 - DOI - PMC - PubMed
-
- malERA Consultative Group on Drugs. A research agenda for malaria eradication: drugs. PLoS Med. 2011;8(1):e1000402 doi: 10.1371/journal.pmed.1000402 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical